Cellworks
Cellworks is a life sciences technology company using mechanistic AI computational biosimulation to predict personalized cancer therapy responses for oncologists, pharmaceutical companies, and payers via its CLIA-certified lab and Singula TRI reports.
- Company typePrivate
- Founded2005
- HeadquartersSouth San Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Cellworks does
Cellworks is a life sciences technology company founded in 2005 and headquartered in South San Francisco, with an R&D center in Bangalore, India. The company has built a proprietary Computational Biology Model (CBM)—a mechanistic network of more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions—and applies it to predict patient-specific therapy response in oncology using multi-omics data (genomic, proteomic, transcriptomic, epigenomic). Its clinical products include the Singula™ Therapy Response Index (TRI) reports, the ΔTRI classifier for metastatic NSCLC chemo-immunotherapy benefit prediction, a Drug-Drug Interaction (DDI) risk assessment tool, and liquid biopsy analysis, all delivered through a physician portal and supported by a CLIA-certified computational laboratory in Franklin, Tennessee.
The company operates two primary revenue motions: a clinical decision support service delivering personalized therapy predictions to oncologists and health systems, and a pharma services business offering virtual clinical trials, target identification, lead validation, and drug repurposing/rescue to biopharmaceutical clients. GTM is enterprise field sales targeting pharma R&D teams, medical directors at health systems, and practicing oncologists, supplemented by a strong scientific conference and peer-reviewed publication presence at ASCO, ASH, AACR, and WCLC. Backed by Artiman Ventures, Sequoia Capital, UnitedHealth Group, Bering Capital, and Agilent Ventures, Cellworks has raised approximately $33M in disclosed funding across rounds (2009, 2012, 2020), with the most recent $15.5M round in June 2020. Board advisors include former ASCO CEO Dr. Allen Lichter and former UnitedHealth Group Cancer Director Dr. Lee Newcomer.
Cellworks firmographics
Firmographics- Name
- Cellworks
- Legal name
- Cell Works Group, Inc.
- Website
- https://cellworks.life
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Cellworks is a life sciences technology company using mechanistic AI computational biosimulation to predict personalized cancer therapy responses for oncologists, pharmaceutical companies, and payers via its CLIA-certified lab and Singula TRI reports.
- Ownership category
- akta.pro rank
Cellworks industry classification
Industry- Product category
- Computational Precision Medicine / Oncology Decision Support
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Molecular Tumor Boards & Clinical Interpretation ServicesCheminformatics & Molecular Modeling / CADDHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where Cellworks is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Cellworks business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Clinical Decision Support Services: Cellworks provides personalized therapy prediction services to physicians and healthcare systems through its CLIA-certified computational lab, generating revenue from test ordering and analysis services.
- Pharma Drug Development Services: Pharma services include virtual clinical trials, improved target identification, lead validation, and ability to repurpose and rescue drugs using the biosimulation platform.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Cellworks product offering
Product offeringCore offering
Cellworks provides a computational biosimulation platform that uses mechanistic AI and multi-omics modeling to predict patient-specific cancer therapy response. Its core engine, the Computational Biology Model (CBM), biosimulates how FDA-approved drugs and combinations affect disease pathways using genomic, proteomic, transcriptomic, and epigenomic data. Outputs are delivered as Singula TRI reports through a CLIA-certified lab and physician portal for clinical decision support, and as pharma services for drug development, virtual trials, and drug repurposing.
Product overview
Cellworks offers a unified biosimulation platform with multiple integrated products and services. The core is the Cellworks Biosimulation Platform powered by the Computational Biology Model (CBM), a mechanistic network of 6,000+ genes used to predict therapy response. This platform is accessed through physician-facing Singula™ TRI reports and a physician portal. The myCare™ clinical trial suite provides clinical study services that generate personalized therapy predictions. Additional products include the ΔTRI classifier for NSCLC treatment selection, a DDI risk assessment tool for oncology, and liquid biopsy analysis capabilities. Services span clinical decision support for physicians, payer solutions for insurance providers, and pharma services for drug development. The company also operates a CLIA-certified computational lab in Franklin, Tennessee.
Differentiator
Problem solved
Functional benefit
Brands
- Singula: Personalized therapy response prediction platform that uses multi-omics biosimulation to predict drug efficacy for individual cancer patients.
- myCare
- Singula TRI (Therapy Response Index)
- Singula Lung
- Ventura
Products and services
- Cellworks Biosimulation Platform A computational biology platform that applies mechanistic AI to perform computational biosimulation of protein-protein interactions, enabling in silico modeling of tumor behavior from next-generation sequencing (NGS) data. Used to predict patient-specific therapy response in oncology and other complex diseases.
- Computational Biology Model (CBM) A proprietary mechanistic network model encompassing more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions. The CBM biosimulates how specific compounds or combinations affect disease pathways to produce therapy response predictions.
- Singula TRI (Therapy Response Index) A therapy response prediction tool that delivers personalized overall survival (OS) and progression-free survival (PFS) predictions across multiple cancer types including NSCLC, GBM, LGG, AML, MDS, and pancreatic cancer. Predicts which drug therapies will produce response in a specific patient based on molecular aberrations.
- myCare Clinical Trials A suite of clinical studies (myCare-009, myCare-021, myCare-040) that apply Cellworks biosimulation to interpret NGS data and deliver actionable therapy recommendations. Includes myCare-101, a prospective clinical trial for newly diagnosed, relapsed, or refractory cancer patients.
- Singula Reports Reports delivered to oncologists and patients that predict which FDA-approved cancer therapies will produce response for a specific patient based on molecular aberrations, overcoming the 'one-mutation one-drug' limitation of standard NGS analysis.
- Singula Ventura A variant of the Singula therapy response prediction report offered through the myCare clinical trial program for cancer patients.
- Physician Portal A web portal enabling qualified healthcare professionals to order tests, access patient information, laboratory test results, and relevant documentation to support personalized therapy decision-making.
- ΔTRI Classifier A novel classifier developed from the myCare-040 clinical study that uses tumor-specific genomic data to predict which metastatic NSCLC patients are likely to benefit from chemo-immunotherapy versus immunotherapy alone. A ΔTRI score ≥16 identifies patients likely to gain 8.3 months median OS improvement.
- DDI Risk Assessment Tool A mechanistically-based drug-drug interaction risk assessment tool that integrates FDA drug label data with gene-level mechanistic insights to identify and classify clinically relevant DDIs in cancer combination therapies. Achieved 100% accuracy against curated datasets.
- Liquid Biopsy Analysis Liquid biopsy genomic profiling as an alternative to solid tissue profiling for predicting benefit from chemo-immunotherapy in advanced NSCLC. Cellworks' predictive scores derived from liquid biopsy samples show strong alignment with solid tissue scores (R² = 0.61).
- CLIA-Certified Computational Lab A CLIA-certified computational laboratory in Franklin, Tennessee that performs genomic biosimulation testing to advance personalized therapy decision support services.
- Payer Solutions Services for payers providing effective intervention recommendations for better patient outcomes, prolonging lives and reducing costs through precision medicine approaches.
- Pharma Services Precision drug development services including virtual clinical trials, improved target identification, lead validation, and drug repurposing/rescue programs for biopharma companies.
Quantifiable outcome
- 90% accuracy in predicting therapy response for AML and MDS patients
- +4 more outcomes
Companies that use Cellworks
Customer profileSegments4 records
Ideal customer profiles3 records
Cellworks technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature5 records
Cellworks partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Global Research CollaboratorscoreCellworks collaborates with global partners on clinical research, with findings featured in 125+ peer-reviewed presentations and publications.
- University of PennsylvaniacoreCharu Aggarwal, MD from Perelman School of Medicine serves as Co-Principal Investigator on myCare-040 study for NSCLC research.
- University of Colorado School of MedicinecoreTejas Patil, MD serves as Co-Principal Investigator on NSCLC clinical studies.
- City of HopecoreDr. Guido Marcucci and Dr. Anthony Stein served as Primary Investigators for myCare-009-01 and myCare-009-02 AML and MDS clinical studies.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Cellworks competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine: Foundation Medicine (Roche subsidiary) is a leading molecular profiling company that provides genomic analysis and clinical decision support for oncology patients. It competes directly with Cellworks' Singula clinical decision support offering while operating at much larger scale with established hospital integrations.
- Guardant Health: Guardant Health is a leader in liquid biopsy and genomic profiling for oncology. Its Guardant360 CDx test competes with Cellworks' solid tissue and liquid biopsy Singula workflow, and it has deeper payer reimbursement infrastructure.
Direct peers
- Tempus Labs: Tempus is a precision medicine company combining multi-omics data, AI, and clinical decision support for oncology. Both companies leverage NGS + AI to predict therapy response and offer pharma R&D services, making Tempus the closest direct competitor in both clinical and pharma verticals.
- MolecularHealth: MolecularHealth offers a treatment decision support platform that matches patient molecular data with drug response evidence. Its functional overlap with Singula's therapy response prediction positions it as a direct niche competitor in molecular tumor board informatics.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven therapy decision support across multiple cancer types. It overlaps directly with Cellworks on multi-omics based therapy response prediction and serves a similar oncologist customer base.
Emerging players
- Inspirata: Inspirata provides a digital pathology and cancer diagnostics platform leveraging AI for oncology decision support and clinical trial workflows. It overlaps with Cellworks' clinical decision support and pharma trial services verticals.
- Exscientia: Exscientia is an AI-driven drug discovery company that uses precision medicine platforms for both pharma partnerships and patient stratification. It overlaps with Cellworks' pharma services (target ID, lead optimization, virtual trials) and is developing precision oncology capabilities.
- PathAI: PathAI applies AI to pathology and precision oncology, including diagnostic decision support and pharma biomarker discovery. It serves a similar customer base (oncologists, pharma R&D) and competes for AI-driven oncology analytics budgets.
- GNS Healthcare: GNS Healthcare applies causal AI and biosimulation to drug discovery and clinical development for pharma partners. Its mechanism-based AI modeling approach is highly analogous to Cellworks' CBM and competes for pharma services budgets.
- Owkin: Owkin applies AI to patient data for drug discovery and clinical research across pharma and provider markets. It overlaps with Cellworks' pharma services vertical (target ID, clinical trial optimization) and is building AI-driven oncology decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cellworks social profiles
Digital presenceCellworks compliance and trust
Trust signalCompliance4 records
Cellworks financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellworks leadership team
Management profileNumber of profiles
Profiles8 records
Cellworks funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellworks M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellworks
What does Cellworks do?
Cellworks provides a computational biosimulation platform that uses mechanistic AI and multi-omics modeling to predict patient-specific cancer therapy response. Its core engine, the Computational Biology Model (CBM), biosimulates how FDA-approved drugs and combinations affect disease pathways using genomic, proteomic, transcriptomic, and epigenomic data. Outputs are delivered as Singula TRI reports through a CLIA-certified lab and physician portal for clinical decision support, and as pharma services for drug development, virtual trials, and drug repurposing.
Is Cellworks a public or private company?
Cellworks is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellworks founded?
Cellworks was founded in 2005. It employs 101 to 250 people.
Where is Cellworks based?
Cellworks is headquartered in South San Francisco, United States, in the North America region.
How does Cellworks make money?
Two revenue lines are on record. Clinical Decision Support Services are the primary driver. The others are pharma Drug Development Services.
Who are Cellworks's main competitors?
Broad incumbents on record are Foundation Medicine and Guardant Health. Direct peers are Tempus Labs, MolecularHealth and Caris Life Sciences. Emerging players are Inspirata, Exscientia, PathAI, GNS Healthcare and Owkin.
Does Cellworks have an API?
No public API is recorded for Cellworks.
What industry is Cellworks in?
Cellworks's product category is Computational Precision Medicine / Oncology Decision Support. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 5417 and its SIC code is 8731.